## DARTEIL et al. U.S. National Phase of PCT/FR2004/000319

### **AMENDMENTS TO THE CLAIMS**

Amend the claims as follows:

Claims 1-17. (cancelled)

18. (new) A compound represented by general formula (I):

$$\begin{array}{c|c} R2 & G_2 & N & R1 \\ G_3 & R3 & \\ & & R3 & \\ & & & & \end{array}$$

in which:

(

- G2 and G3 independently represent an oxygen atom, a sulfur atom or a N-R4 group, wherein G2 and G3 do not simultaneously represent a N-R4 group,
- R and R4 independently represent a hydrogen atom or a linear or branched alkyl group, saturated or not, optionally substituted, containing from 1 to 5 carbon atoms,

## DARTEIL et al. U.S. National Phase of PCT/FR2004/000319

- R1, R2 and R3, which are the same or different, represent a hydrogen atom, a
   CO-R5 group or a group corresponding to the formula CO-(CH<sub>2</sub>)<sub>2n+1</sub>-X-R6,
   wherein at least one of the groups R1, R2 or R3 is a group corresponding to the formula CO-(CH<sub>2</sub>)<sub>2n+1</sub>-X-R6,
- R5 is a linear or branched alkyl group, saturated or not, optionally substituted, optionally comprising a cyclic group, the main chain of which contains from 1 to 25 carbon atoms,
- X is a sulfur atom, a selenium atom, a SO group or a SO<sub>2</sub> group
- n is a whole number comprised between 0 and 11,
- R6 is a linear or branched alkyl group, saturated or not, optionally substituted, optionally comprising a cyclic group, the main chain of which contains from 3 to 23 carbon atoms, preferably 10 to 23 carbon atoms and possibly one or more heterogroups selected in the group consisting of an oxygen atom, a sulfur atom, a selenium atom, a SO group and a SO<sub>2</sub> group,

with the exception of a compound represented by formula (I) in which G2R2 and G3R3 simultaneously represent hydroxyl groups,

## **DARTEIL** et al.

#### U.S. National Phase of PCT/FR2004/000319

the optical and geometrical isomer, racemate, salt, hydrate thereof and mixtures thereof.

- 19. (new) The compound according to claim 18, wherein a single one of the groups R1, R2 or R3 represents a hydrogen atom.
- 20. (new) The compound according to claim 18, wherein, in the CO-(CH<sub>2</sub>)<sub>2n+1</sub>-X-R6 group, X represents a sulfur or selenium atom and advantageously a sulfur atom.
- 21. (new) The compound according to claim 18, wherein, in the CO- $(CH_2)_{2n+1}$ -X-R6 group, n is comprised between 0 and 3, more specifically comprised between 0 and 2 and in particular is equal to 0.
- 22. (new) The compound according to claim 18, wherein R6 contains one or more heterogroups, preferably 0, 1 or 2, more preferably 0 or 1, selected in the group consisting of an oxygen atom, a sulfur atom, a selenium atom, a SO group and a SO<sub>2</sub> group.
- 23. (new) The compound according to claim 18, wherein CO-(CH<sub>2</sub>)<sub>2n+1</sub>-X-R6 is the CO-CH<sub>2</sub>-S-C<sub>14</sub>H<sub>29</sub> group.

#### DARTEIL et al.

### U.S. National Phase of PCT/FR2004/000319

- 24. (new) The compound according to claim 18, wherein at least one of the groups R1, R2 and R3 represents a CO-(CH<sub>2</sub>)<sub>2n+1</sub>-X-R6 group in which X represents a sulfur or selenium atom and preferably a sulfur atom and/or R6 is a saturated and linear alkyl group containing from 3 to 23 carbon atoms, preferably 13 to 20 carbon atoms, preferably 14 to 17, more preferably 14 to 16, and even more preferably 14 carbon atoms.
- 25. (new) The compound according to claim 18, wherein at least two of the groups R1, R2 and R3 are CO-(CH<sub>2</sub>)<sub>2n+1</sub>-X-R6 groups, which are the same or different, in which X represents a sulfur or selenium atom, preferably a sulfur atom.
- 26. (new) The compound according to claim 18, wherein G2 represents an oxygen or sulfur atom, preferably an oxygen atom.
- 27. (new) The compound according to claim 18, wherein G2 represents an oxygen or sulfur atom and R2 represents a group corresponding to the formula CO-(CH<sub>2</sub>)<sub>2n+1</sub>-X-R6.
  - 28. (new) The compound according to claim 18, wherein:
    - G3 is a N-R4 group in which R4 is a hydrogen atom or a methyl group,
       and G2 is an oxygen atom; and/or
      - R2 represents a CO-(CH<sub>2</sub>)<sub>2n+1</sub>-X-R6 group.

# DARTEIL et al. U.S. National Phase of PCT/FR2004/000319

29. (new) The compound according to claim 18, wherein R1, R2 and R3, which are the same or different, preferably the same, represent a CO-(CH<sub>2</sub>)<sub>2n+1</sub>-X-R6 group, in which X represents a sulfur or selenium atom and preferably a sulfur atom and/or R6 is a saturated and linear alkyl group containing from 13 to 17 carbon atoms, preferably 14 to 17, even more preferably 14 carbon atoms, in which n is preferably comprised between 0 and 3, and in particular is equal to 0, more specifically, R1, R2 and R3 representing CO-CH<sub>2</sub>-S-C<sub>14</sub>H<sub>29</sub> groups.

30. (new) The compound according to claim 18, selected in the group consisting of :

- 1-tetradecylthioacetylamino-2,3-(dipalmitoyloxy)propane;
- 3-tetradecylthioacetylamino-1,2-(ditetradecylthioacetyloxy)propane;
- 3-palmitoylamino-1,2-(ditetradecylthioacetyloxy)propane;
- 1,3-di(tetradecylthioacetylamino)propan-2-ol;
- 1,3-diamino-2-(tetradecylthioacetyloxy) propane;
- 1,3-ditetradecylthioacetylamino-2-(tetradecylthioacetyloxy)propane;
- 1,3-dioleoylamino-2-(tetradecylthioacetyloxy)propane;
- 1,3-ditetradecylthioacetylamino-2-(tetradecylthioacetylthio)propane; and
- 1-tetradecylthioacetylamino-2,3-di(tetradecylthioacetylthio)propane.

31. (new) A pharmaceutical composition comprising, in a pharmaceutically acceptable support, at least one compound represented by formula (I) such as defined

**DARTEIL** et al.

U.S. National Phase of PCT/FR2004/000319

in any of the previous claims, including a compound represented by formula (I) in which the groups G2R2 and G3R3 simultaneously represent hydroxyl groups.

32. (new) The pharmaceutical composition according to claim 31, for the treatment or prophylaxis of cerebrovascular pathologies and more particularly cerebral ischemia or stroke.

33. (new) A method for the treatment of cerebrovascular pathologies and more particularly cerebral ischemia or stroke, by administering to a subject in need of such treatment an effective amount of a compound represented by formula (I) as defined in claim 18, including a compound represented by formula (I) in which the groups G2R2 and G3R3 simultaneously represent hydroxyl groups.